These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 20156067

  • 1. Uncoupling between insulin and release of a D-chiro-inositol-containing inositolphosphoglycan mediator of insulin action in obese women With polycystic ovary syndrome.
    Baillargeon JP, Iuorno MJ, Apridonidze T, Nestler JE.
    Metab Syndr Relat Disord; 2010 Apr; 8(2):127-36. PubMed ID: 20156067
    [Abstract] [Full Text] [Related]

  • 2. Metformin therapy increases insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator in women with polycystic ovary syndrome.
    Baillargeon JP, Iuorno MJ, Jakubowicz DJ, Apridonidze T, He N, Nestler JE.
    J Clin Endocrinol Metab; 2004 Jan; 89(1):242-9. PubMed ID: 14715857
    [Abstract] [Full Text] [Related]

  • 3. Pioglitazone Therapy Increases Insulin-Stimulated Release of d-Chiro-Inositol-Containing Inositolphosphoglycan Mediator in Women with Polycystic Ovary Syndrome.
    Gupta A, Jakubowicz D, Nestler JE.
    Metab Syndr Relat Disord; 2016 Oct; 14(8):391-396. PubMed ID: 27028341
    [Abstract] [Full Text] [Related]

  • 4. Insulin-stimulated release of D-chiro-inositol-containing inositolphosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome.
    Cheang KI, Baillargeon JP, Essah PA, Ostlund RE, Apridonize T, Islam L, Nestler JE.
    Metabolism; 2008 Oct; 57(10):1390-7. PubMed ID: 18803944
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients.
    Genazzani AD, Prati A, Santagni S, Ricchieri F, Chierchia E, Rattighieri E, Campedelli A, Simoncini T, Artini PG.
    Gynecol Endocrinol; 2012 Dec; 28(12):969-73. PubMed ID: 22612517
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Role of inositolphosphoglycan mediators of insulin action in the polycystic ovary syndrome.
    Nestler JE, Jakubowicz DJ, Iuorno MJ.
    J Pediatr Endocrinol Metab; 2000 Dec; 13 Suppl 5():1295-8. PubMed ID: 11117673
    [Abstract] [Full Text] [Related]

  • 12. The metabolic status modulates the effect of metformin on the antimullerian hormone-androgens-insulin interplay in obese women with polycystic ovary syndrome.
    Romualdi D, De Cicco S, Tagliaferri V, Proto C, Lanzone A, Guido M.
    J Clin Endocrinol Metab; 2011 May; 96(5):E821-4. PubMed ID: 21307134
    [Abstract] [Full Text] [Related]

  • 13. Hyperinsulinemia is closely related to low urinary clearance of D-chiro-inositol in men with a wide range of insulin sensitivity.
    Villeneuve MC, Ostlund RE, Baillargeon JP.
    Metabolism; 2009 Jan; 58(1):62-8. PubMed ID: 19059532
    [Abstract] [Full Text] [Related]

  • 14. Reflections on inositol(s) for PCOS therapy: steps toward success.
    Nestler JE, Unfer V.
    Gynecol Endocrinol; 2015 Jul; 31(7):501-5. PubMed ID: 26177098
    [Abstract] [Full Text] [Related]

  • 15. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF, Nilas L, Madsbad S, Holst JJ.
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [Abstract] [Full Text] [Related]

  • 16. Normal metabolic flexibility despite insulin resistance women with polycystic ovary syndrome.
    Adamska A, Karczewska-Kupczewska M, Nikołajuk A, Otziomek E, Górska M, Kowalska I, Strączkowski M.
    Endocr J; 2013 May; 60(9):1107-13. PubMed ID: 23801024
    [Abstract] [Full Text] [Related]

  • 17. Alteration of ghrelin-neuropeptide Y network in obese patients with polycystic ovary syndrome: role of hyperinsulinism.
    Romualdi D, De Marinis L, Campagna G, Proto C, Lanzone A, Guido M.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):562-7. PubMed ID: 18248643
    [Abstract] [Full Text] [Related]

  • 18. Total ghrelin levels during acute insulin infusion in patients with polycystic ovary syndrome.
    Micic D, Sumarac-Dumanovic M, Kendereski A, Cvijovic G, Zoric S, Pejkovic D, Micic J, Milic N, Dieguez C, Casanueva FF.
    J Endocrinol Invest; 2007 Nov; 30(10):820-7. PubMed ID: 18075283
    [Abstract] [Full Text] [Related]

  • 19. Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance.
    Arslanian SA, Lewy V, Danadian K, Saad R.
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1555-9. PubMed ID: 11932281
    [Abstract] [Full Text] [Related]

  • 20. Familial diabetes predisposes PCOS patients to insulin resistance (IR), reproductive impairment and hepatic dysfunction: effects of d-chiro inositol (DCI) and alpha lipoic acid (ALA) administration on hepatic insulin extraction (HIE) index.
    Genazzani AD, Battipaglia C, Petrillo T, Piacquadio N, Ambrosetti F, Arnesano M, Semprini E, Sponzilli A, Tomatis V, Simoncini T.
    Gynecol Endocrinol; 2022 Aug; 38(8):681-688. PubMed ID: 35748584
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.